The Africa Medicines Impact Investment Fund

  • Trustfeed ratings Icon
  • Trustfeed ratings Icon
  • Trustfeed ratings Icon
  • Trustfeed ratings Icon
  • Trustfeed ratings Icon

Port Louis, Mauritius

Investment Management

The Africa Medicines Impact Investment Fund Reviews | Rating 3 out of 5 stars (5 reviews)

The Africa Medicines Impact Investment Fund is rated 3 out of 5 in the category investment management. Read and write reviews about The Africa Medicines Impact Investment Fund. The Africa Medicines Impact Investment Fund (AMIIF) is an innovative purpose-driven investment vehicle that will deliver measurable social and development impacts by increasing access to affordable, good quality medicines and diagnostics in sub-Saharan Africa, through providing capital for initiating and scaling up regional pharmaceutical marketplace innovations and social-purpose business initiatives which have a measurable impact on achieving this objective. The Fund believes that investing in ventures that have both social and commercial returns can lead to significant development outcomes that are sustainable in the long run. Further to which, the Fund believes that such a structure can act as a catalyst for private sector investment where previously it has been dominated by public sector funding. The primary objective of the Fund is to deliver measurable social and development impacts by increasing access to affordable, good quality essential medicines in Sub-Saharan Africa, through providing debt funding for initiating and scaling up regional pharmaceutical marketplace innovations and social-purpose business initiatives. The Fund has both social and financial objectives.

Address

4th Floor, Unicorn Centre 18N, Frere Félix De Valois Street

Company size

11-50 employees

Headquarters

Port Louis

Founded

2012

Open hours

...
There is no reviews yet about The Africa Medicines Impact Investment Fund, be the first to write a review and give your rating to The Africa Medicines Impact Investment Fund
Write review Claim Profile